Summary

The chemiluminescence immunoassay market is projected to reach USD 16.39 billion by 2031 from USD 11.58 billion in 2026, at a CAGR of 7.2% from 2026 to 2031.

https://mnmimg.marketsandmarkets.com/Images/chemiluminescence-immunoassay-clia-market1-img-overview.webp

The global market for CLIA testing systems is growing as people need accurate diagnostic tests to identify chronic and infectious diseases, including cancer, cardiovascular disorders, thyroid diseases, and viral infections. The increasing need for early disease detection, together with preventive healthcare approaches, leads to greater use of CLIA testing because it provides excellent sensitivity and a wide testing range and can identify trace amounts of biomarkers. The development of automated high-throughput testing systems, together with more stable testing materials and the ability to conduct multiple tests simultaneously, has improved laboratory productivity while decreasing testing duration. The market growth benefits from improved healthcare facilities, expanded testing laboratory systems, and increased medical expenditures that emerging markets are experiencing. The rising importance of biomarker testing for personalized medicine, drug development, and clinical research, together with strict blood screening regulations and health checkup awareness, boosts the need for CLIA systems in hospitals and reference laboratories throughout the world.
“Based on the product, the consumables segment is expected to grow at the highest CAGR in the CLIA market.”
The consumables segment of the CLIA market is growing because diagnostic testing requires laboratories to use reagents, calibrators, controls, and reaction vessels multiple times throughout their workday. Assay kits and reagent packs that hospitals and reference laboratories use daily see increased demand because infectious disease tests, oncology marker tests, cardiac biomarker tests, endocrine disorder tests, and therapeutic drug monitoring tests are being performed more frequently. Consumables require continuous replacement, which generates ongoing revenue while driving market growth, in contrast to analyzers. The adoption of new technologies that enhance reagent stability and ready-to-use product development and extended shelf-life capabilities leads to higher operational efficiency and lower material waste in laboratory workflows. The expansion of automated high-throughput CLIA systems, together with increased preventive health screening programs, higher blood safety testing, and expanded test menu options, is driving up consumables consumption, which makes this segment a key driver of overall CLIA market expansion.

“Based on application, the oncology segment is expected to grow with the highest CAGR in the CLIA market.”
The CLIA market in oncology applications shows growth because cancer cases are increasing worldwide, and there is greater demand for early diagnosis, prognosis evaluation, and treatment assessment. CLIA technology enables the detection of tumor markers through highly sensitive and specific methods, which include PSA, CA-125, CEA, AFP, and HER2 as diagnostic tools for initial patient evaluation and progress assessment of their medical condition. The rise in biomarker-based testing and precision oncology practices has created a need for dependable immunoassays, which assist in determining targeted therapies and individualized treatment options. The clinical use of CLIA tests has grown because these tests now help doctors monitor patient treatment response, identify cancer recurrences, and assess patients who have a high risk of developing cancer. The introduction of better assay systems, which enhance test sensitivity through automated processes and multiplex testing features, will continue to drive businesses toward adopting CLIA systems in their cancer diagnostic processes.

“Based on the end user, the hospitals segment is expected to grow by the highest CAGR in the CLIA market.”
Hospitals need to conduct accurate tests for various medical conditions, including cardiac markers, sepsis indicators, cancer biomarkers, hormone levels, and infectious pathogens. The CLIA systems enable emergency departments, intensive care units, and inpatient services to start treatment without delay through their advanced sensitivity, extensive testing capabilities, and quick result delivery. The move to centralized diagnostic systems, together with automated diagnostic machines, helps hospitals to cut down on manual tasks while achieving better operational results through standardized processes. The worldwide implementation of CLIA analyzers and assays in hospital systems accelerates because hospitals expand their facilities, and preventive health screening programs become more popular, accreditation and quality standards increase, and hospitals need complete laboratory information systems.

“APAC is estimated to register the highest CAGR during the forecast period.”
The CLIA market in the Asia Pacific region is growing due to three factors: expanding healthcare, rising healthcare spending, and improved distribution of diagnostic services in countries such as China, India, and Southeast Asia. The rising need for precise early diagnostic tests results from the increasing incidence of chronic illnesses, infectious diseases, and conditions linked to lifestyle choices. The government modernization projects, which include hospital upgrades, laboratory automation, and the development of a national screening program, accelerate the implementation of high-throughput CLIA systems. The demand for advanced immunoassay technologies grows due to three factors, which include increasing public knowledge about preventive healthcare, expanding private diagnostic laboratory networks, and rising medical tourism. The regional growth of the market benefits from three factors, which include a large patient base, better insurance access, and the market's shift toward automated laboratory systems that manage high testing loads. The widespread implementation of CLIA platforms throughout APAC results from two factors, which include ongoing international diagnostic company expansion and the rise of affordable domestic manufacturers.

Key players in the CLIA market
The key players in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), QuidelOrtho Corporation (US), Sysmex Corporation (Japan), Shenzhen New Industry Biomedical Engineering Co., Ltd. (SNIBE Diagnostics) (China), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), HUMAN Gesellschaft f?r Biochemica und Diagnostica mbH. (Germany), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Agappe Diagnostics Ltd (India), Zecen Biotech Co., Ltd (China), Maccura Biotechnology Co., Ltd (China), Autobio Diagnostics Co., Ltd. (China), Artron Laboratories Inc.(Canada), Abnova Corporation (Taiwan), Beijing Hotgen Biotech Co., Ltd (China), and Shanghai Kehua Bio-Engineering Co., Ltd. (China).
Research Coverage:
The report analyzes the CLIA market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, sample type, technology, application, and end user. The report also includes a product portfolio matrix of various CLIA available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall CLIA market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
? Analysis of key drivers (increasing incidences of chronic and infectious diseases globally, advancements in improving CLIA technologies in recent years, rapid increase in geriatric population globally, growth of biotechnology and biopharmaceutical industries), restraints (high cost associated with placement and maintenance of CLIA, product recalls and failures), challenges (shortage of skilled professionals, risks associated with CLIAs), and opportunities (growth potential in emerging economies)
? Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global CLIA market
? Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global CLIA market
? Market Development: Comprehensive information on the lucrative emerging markets by product type, technology, sample type, application, and end user
? Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global CLIA market
? Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global CLIA market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS COVERED & REGIONAL SCOPE 31
1.3.2 INCLUSIONS & EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 33
1.3.5 UNITS CONSIDERED 33
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 34
2 EXECUTIVE SUMMARY 35
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 35
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS IN CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET 37
2.4 HIGH-GROWTH SEGMENTS 38
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 39
3 PREMIUM INSIGHTS 41
3.1 CHEMILUMINESCENCE IMMUNOASSAY OVERVIEW 41
3.2 ASIA PACIFIC CHEMILUMINESCENCE IMMUNOASSAY, BY PRODUCT AND COUNTRY 42
3.3 CHEMILUMINESCENCE IMMUNOASSAY: DEVELOPED MARKETS VS.
EMERGING ECONOMIES 43
3.4 CHEMILUMINESCENCE IMMUNOASSAY: GEOGRAPHIC GROWTH OPPORTUNITIES 44
3.5 CHEMILUMINESCENCE IMMUNOASSAY: REGIONAL MIX 45
4 MARKET OVERVIEW 46
4.1 INTRODUCTION 46
4.2 MARKET DYNAMICS 47
4.2.1 DRIVERS 47
4.2.1.1 Increasing incidence of chronic and infectious diseases globally 47
4.2.1.2 Advancements in chemiluminescence immunoassay technologies in recent years 49
4.2.1.3 Rapid increase in geriatric population globally 50
4.2.1.4 Growth of biotechnology and biopharmaceutical industries 51
4.2.2 RESTRAINTS 52
4.2.2.1 High cost of chemiluminescence systems and reagents 52
4.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 52
4.2.3 OPPORTUNITIES 53
4.2.3.1 High growth prospects for players in emerging economies 53
4.2.3.2 Increasing number of collaborations and partnerships 54
4.2.4 CHALLENGES 54
4.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 54
4.2.4.2 Lack of skilled professionals and aging workforce 55
4.3 UNMET NEEDS & WHITE SPACES 55
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 57
4.4.1 INTERCONNECTED MARKETS 57
4.4.2 CROSS-SECTOR OPPORTUNITIES 58
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 58
5 INDUSTRY TRENDS 60
5.1 PORTER’S FIVE FORCES ANALYSIS 60
5.1.1 THREAT OF NEW ENTRANTS 61
5.1.2 THREAT OF SUBSTITUTES 61
5.1.3 BARGAINING POWER OF SUPPLIERS 62
5.1.4 BARGAINING POWER OF BUYERS 62
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 62
5.2 MACROECONOMIC INDICATORS 62
5.2.1 INTRODUCTION 62
5.2.2 GDP TRENDS & FORECAST 62
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 64
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 65
5.3 VALUE CHAIN ANALYSIS 66
5.4 SUPPLY CHAIN ANALYSIS 67
5.5 ECOSYSTEM ANALYSIS 68
5.6 PRICING ANALYSIS 70
5.6.1 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY KEY PLAYER, 2023?2025 (USD) 71
5.6.2 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY REGION, 2023?2025 (USD) 71
5.6.3 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY ANALYZERS, BY TECHNOLOGY, 2023?2025 (USD) 73
5.6.4 AVERAGE SELLING PRICE TREND OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES (KITS, REAGENTS, AND OTHERS), BY SAMPLE TYPE,
2023?2025 (USD) 73
5.7 TRADE ANALYSIS 73
5.7.1 IMPORT DATA FOR HS CODE 9027.89, 2021?2025 74
5.7.2 EXPORT DATA FOR HS CODE 9027.89, 2021?2025 74
5.8 KEY CONFERENCES & EVENTS, 2026?2027 75
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
5.10 INVESTMENT & FUNDING SCENARIO 77
5.11 CASE STUDY ANALYSIS 78
5.11.1 CASE STUDY 1: ROCHE COBAS CLIA DRIVES HIGH-VOLUME TESTING PERFORMANCE 78
5.11.2 CASE STUDY 2: ABBOTT ARCHITECT DRIVES REGIONAL
MULTI-CENTER LAB EXPANSION 78
5.11.3 CASE STUDY 3: SIEMENS ADVIA CENTAUR XP BOOSTS
GOVERNMENT LAB TESTING EFFICIENCY 79
5.12 IMPACT OF 2025 US TARIFFS ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 79
5.12.1 INTRODUCTION 79
5.12.2 KEY TARIFF RATES 80
5.12.3 PRICE IMPACT ANALYSIS 81
5.12.4 IMPACT ON COUNTRIES/REGIONS 81
5.12.4.1 US 81
5.12.4.2 Europe 81
5.12.4.3 Asia Pacific 82
5.12.5 IMPACT ON END-USE INDUSTRIES 82
5.12.5.1 Hospitals 82
5.12.5.2 Clinical laboratories 82
5.12.5.3 Pharmaceutical & biotechnology companies and contract research organizations 83
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND
DIGITAL & AI ADOPTION 84
6.1 TECHNOLOGY ANALYSIS 84
6.1.1 KEY EMERGING TECHNOLOGIES 84
6.1.1.1 Nano-engineered chemiluminescent labels 84
6.1.1.2 Digital immunoassay platforms 84
6.1.2 COMPLEMENTARY TECHNOLOGIES 84
6.1.2.1 Bead-based & microarray chemiluminescence 84
6.1.2.2 Integration with microfluidic platforms 85
6.1.3 ADJACENT TECHNOLOGIES 85
6.1.3.1 Enzyme-linked immunosorbent assay (ELISA) 85
6.2 TECHNOLOGY/PRODUCT ROADMAP 85
6.3 PATENT ANALYSIS 86
6.3.1 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS, AND JURISDICTION FOR CHEMILUMINESCENCE IMMUNOASSAY MARKET, JANUARY 2015?SEPTEMBER 2025 86
6.3.2 LIST OF MAJOR PATENTS, 2022?2025 88
6.4 FUTURE APPLICATIONS 89
6.4.1 PERSONALIZED & PRECISION MEDICINE 89
6.4.2 REMOTE MONITORING & DECENTRALIZED TESTING 89
6.4.3 PREDICTIVE DIAGNOSTICS & CLINICAL DECISION SUPPORT 89
6.4.4 INTEGRATION WITH DIGITAL HEALTH ECOSYSTEMS 89
6.4.5 NEXT-GENERATION BIOMARKER DISCOVERY & MULTIPLEX TESTING 90
6.5 IMPACT OF GEN AI ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 90
6.5.1 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 92
6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 92
6.6.1 IMPROVED OUTCOMES IN CRITICAL CARE & EMERGENCY DIAGNOSTICS 92
6.6.2 PUBLIC HEALTH SCREENING & INFECTIOUS DISEASE CONTROL 92
6.6.3 ENDOCRINOLOGY & CHRONIC DISEASE MANAGEMENT 93
6.6.4 ONCOLOGY DIAGNOSTICS & THERAPY MONITORING 93
6.6.5 MATERNAL & NEONATAL SCREENING PROGRAMS 93
6.6.6 DECENTRALIZED & MID-VOLUME LABORATORY ADOPTION 93
6.6.7 REAL-WORLD IMPACT 93
7 SUSTAINABILITY & REGULATORY LANDSCAPE 94
7.1 REGULATORY LANDSCAPE 94
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
7.1.2 INDUSTRY STANDARDS 97
7.1.2.1 ISO 15189 ? Quality & competence requirements for medical laboratories 97
7.1.2.2 CLSI Guidelines (Clinical & Laboratory Standards Institute) ? Immunoassay performance & validation 97
7.1.2.3 ISO 13485 ? Quality management systems for IVD manufacturers 97
7.1.2.4 ISO 17511 ? Metrological traceability of calibrators & control materials 97
7.2 SUSTAINABILITY INITIATIVES 97
7.2.1 REAGENT PACKAGING REDUCTION & RECYCLABLE MATERIALS (INDUSTRY INITIATIVES) 98
7.2.2 ENERGY-EFFICIENT & LOW-WASTE ANALYZER OPERATIONS 98
7.2.3 LABORATORY WASTE MANAGEMENT & GREEN LAB PROGRAMS 98
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
7.3.1 CERTIFICATIONS & LABELING STANDARDS 98
7.3.2 ECO-STANDARDS & SUSTAINABILITY CONSIDERATIONS 99
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
8.1 DECISION-MAKING PROCESS 100
8.2 KEY STAKEHOLDERS & BUYING CRITERIA 101
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
8.2.1.1 Influence of stakeholders on buying process for product types 101
8.2.2 BUYING CRITERIA 102
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS 104
8.5 MARKET PROFITABILITY 105
8.5.1 REVENUE POTENTIAL 105
8.5.2 COST DYNAMICS 105
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT TYPE 106
9.1 INTRODUCTION 107
9.2 CONSUMABLES 107
9.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST MARKET SHARE
DURING STUDY PERIOD 107
9.3 INSTRUMENTS 109
9.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET 109
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY 113
10.1 INTRODUCTION 114
10.2 CHEMILUMINESCENCE ENZYME IMMUNOASSAYS 114
10.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET 114
10.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAYS 116
10.3.1 RISING DEMAND FOR HIGH-SENSITIVITY CARDIAC AND ONCOLOGY BIOMARKERS TO DRIVE MARKET 116
10.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAYS 118
10.4.1 SUPERIOR SENSITIVITY AND EARLY DISEASE DETECTION TO DRIVE MARKET GROWTH 118
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE 120
11.1 INTRODUCTION 121
11.2 BLOOD 121
11.2.1 RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET 121
11.3 URINE 122
11.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET 122
11.4 SALIVA 124
11.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET 124
11.5 OTHER SAMPLE TYPES 125
12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION 126
12.1 INTRODUCTION 127
12.2 INFECTIOUS DISEASES 128
12.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 128
12.3 ENDOCRINOLOGY 129
12.3.1 RISING INCIDENCES OF DIABETES TO PROPEL DEMAND FOR DIAGNOSTICS 129
12.4 ONCOLOGY 131
12.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY
DISEASE DIAGNOSIS TO DRIVE MARKET 131
12.5 CARDIOLOGY 133
12.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET 133
12.6 ALLERGY DIAGNOSTICS 135
12.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS 135
12.7 BLOOD SCREENING 136
12.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET 136
12.8 AUTOIMMUNE DISORDERS 138
12.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET 138
12.9 BONE & MINERAL DISORDERS 140
12.9.1 HIGH DISORDER PREVALENCE TO OFFER STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 140
12.10 TOXICOLOGY 142
12.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 142
12.11 NEWBORN SCREENING 144
12.11.1 ROUTINE USE IN FIRST-TIER NEWBORN SCREENING PROTOCOL TO SUSTAIN DEMAND 144
12.12 THERAPEUTIC DRUG MONITORING 145
12.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET 145
12.13 METABOLIC DISORDERS 147
12.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 147
12.14 GASTROENTEROLOGY 149
12.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET 149
12.15 NEUROLOGY 150
12.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT 150
12.16 RESPIRATORY DISEASES 152
12.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY
DISEASES TO DRIVE MARKET 152
12.17 OTHER APPLICATIONS 153
13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER 155
13.1 INTRODUCTION 156
13.2 HOSPITALS 156
13.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES ENSURE LEADERSHIP OF HOSPITALS 156
13.3 CLINICAL LABORATORIES 159
13.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT 159
13.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS 160
13.4.1 RISING DRUG DISCOVERY ACTIVITY AND CLINICAL STUDIES
TO DRIVE MARKET 160
13.5 OTHER END USERS 162
14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION 164
14.1 INTRODUCTION 165
14.1.1 GLOBAL: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 165
14.2 NORTH AMERICA 166
14.2.1 MACROECONOMIC OUTLOOK 166
14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 169
14.2.3 US 172
14.2.3.1 US to hold largest share of North American market during forecast period 172
14.2.4 CANADA 176
14.2.4.1 Rising government initiatives and funding for early disease diagnosis to drive market 176
14.3 EUROPE 181
14.3.1 MACROECONOMIC OUTLOOK 182
14.3.2 EUROPE: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 184
14.3.3 GERMANY 187
14.3.3.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 187
14.3.4 FRANCE 192
14.3.4.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 192
14.3.5 UK 197
14.3.5.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 197
14.3.6 ITALY 202
14.3.6.1 Growing geriatric population and increasing support for research to drive market 202
14.3.7 SPAIN 206
14.3.7.1 Rising adoption of technologically advanced immunoassay systems to drive market 206
14.3.8 REST OF EUROPE 210
14.4 ASIA PACIFIC 214
14.4.1 MACROECONOMIC OUTLOOK 215
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 218
14.4.3 JAPAN 221
14.4.3.1 Growing investments in clinical diagnostics research to drive market 221
14.4.4 CHINA 225
14.4.4.1 China to register highest growth rate in Asia Pacific market during study period 225
14.4.5 INDIA 230
14.4.5.1 Growing medical tourism and healthcare infrastructure
to drive market 230
14.4.6 SOUTH KOREA 234
14.4.6.1 Rising healthcare spending for innovative IVD technologies
to drive market 234
14.4.7 AUSTRALIA 238
14.4.7.1 Rising healthcare spending for innovative IVD technologies
to drive market 238
14.4.8 REST OF ASIA PACIFIC 242
14.5 LATIN AMERICA 246
14.5.1 MACROECONOMIC OUTLOOK 247
14.5.2 LATIN AMERICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 248
14.5.3 BRAZIL 251
14.5.3.1 Improving healthcare facilities to drive market 251
14.5.4 MEXICO 255
14.5.4.1 Robust healthcare system to drive market growth in Mexico 255
14.5.5 REST OF LATIN AMERICA 259
14.6 MIDDLE EAST & AFRICA 263
14.6.1 MACROECONOMIC OUTLOOK 264
14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS, 2024?2031 (HUNDRED UNITS) 265
14.6.3 GCC COUNTRIES 268
14.6.4 REST OF MIDDLE EAST & AFRICA 272
15 COMPETITIVE LANDSCAPE 277
15.1 OVERVIEW 277
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023?2026 277
15.3 REVENUE ANALYSIS, 2021?2025 279
15.4 MARKET SHARE ANALYSIS, 2025 280
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 282
15.5.1 STARS 282
15.5.2 EMERGING LEADERS 283
15.5.3 PERVASIVE PLAYERS 283
15.5.4 PARTICIPANTS 283
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 284
15.5.5.1 Company footprint 284
15.5.5.2 Region footprint 285
15.5.5.3 Product type footprint 286
15.5.5.4 Technology footprint 287
15.5.5.5 Sample type footprint 288
15.5.5.6 Application footprint 289
15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025 291
15.6.1 PROGRESSIVE COMPANIES 291
15.6.2 RESPONSIVE COMPANIES 291
15.6.3 DYNAMIC COMPANIES 291
15.6.4 STARTING BLOCKS 291
15.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025 293
15.6.5.1 Detailed list of key start-ups/SMEs 293
15.6.5.2 Competitive benchmarking of key start-ups/SMEs 294
15.7 COMPANY VALUATION AND FINANCIAL METRICS 295
15.8 PRODUCT COMPARISON 296
15.8.1 F. HOFFMANN-LA ROCHE LTD 297
15.8.2 DANAHER CORPORATION 297
15.8.3 ABBOTT 297
15.8.4 SIEMENS HEALTHINEERS AG 297
15.8.5 DIASORIN S.P.A 297
15.9 COMPETITIVE SCENARIO 297
16 COMPANY PROFILES 303
16.1 KEY PLAYERS 303
16.1.1 F. HOFFMANN-LA ROCHE LTD 303
16.1.1.1 Business overview 303
16.1.1.2 Products offered 304
16.1.1.3 Recent developments 305
16.1.1.3.1 Product approvals 305
16.1.1.3.2 Deals 305
16.1.1.4 MnM view 305
16.1.1.4.1 Key strengths/Right to win 305
16.1.1.4.2 Strategic choices 306
16.1.1.4.3 Weaknesses/Competitive threats 306
16.1.2 ABBOTT 307
16.1.2.1 Business overview 307
16.1.2.2 Products offered 308
16.1.2.3 Recent developments 309
16.1.2.3.1 Deals 309
16.1.2.4 MnM view 309
16.1.2.4.1 Key strengths/Right to win 309
16.1.2.4.2 Strategic choices 310
16.1.2.4.3 Weaknesses/Competitive threats 310
?
16.1.3 SIEMENS HEALTHINEERS AG 311
16.1.3.1 Business overview 311
16.1.3.2 Products offered 312
16.1.3.3 Recent developments 313
16.1.3.3.1 Deals 313
16.1.3.4 MnM view 314
16.1.3.4.1 Key strengths/Right to win 314
16.1.3.4.2 Strategic choices 314
16.1.3.4.3 Weaknesses/Competitive threats 314
16.1.4 DANAHER CORPORATION 315
16.1.4.1 Business overview 315
16.1.4.2 Products offered 316
16.1.4.3 Recent developments 317
16.1.4.3.1 Deals 317
16.1.4.4 MnM view 317
16.1.4.4.1 Key strengths/Right to win 317
16.1.4.4.2 Strategic choices 317
16.1.4.4.3 Weaknesses/Competitive threats 318
16.1.5 DIASORIN S.P.A. 319
16.1.5.1 Business overview 319
16.1.5.2 Products offered 321
16.1.5.3 Recent developments 321
16.1.5.3.1 Product approvals 321
16.1.5.3.2 Deals 321
16.1.5.4 MnM view 322
16.1.5.4.1 Key strengths/Right to win 322
16.1.5.4.2 Strategic choices 322
16.1.5.4.3 Weaknesses/Competitive threats 322
16.1.6 QUIDELORTHO CORPORATION 323
16.1.6.1 Business overview 323
16.1.6.2 Products offered 324
16.1.6.3 Recent developments 325
16.1.6.3.1 Deals 325
16.1.7 SYSMEX CORPORATION 326
16.1.7.1 Business overview 326
16.1.7.2 Products offered 327
16.1.7.3 Recent developments 328
16.1.7.3.1 Product launches 328
16.1.7.3.2 Deals 329
?
16.1.8 SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. 330
16.1.8.1 Business overview 330
16.1.8.2 Products offered 331
16.1.8.3 Recent developments 332
16.1.8.3.1 Product approvals 332
16.1.9 TOSOH CORPORATION 333
16.1.9.1 Business overview 333
16.1.9.2 Products offered 335
16.1.9.3 Recent developments 336
16.1.9.3.1 Product launches 336
16.1.10 WERFEN 337
16.1.10.1 Business overview 337
16.1.10.2 Products offered 338
16.1.10.3 Recent developments 339
16.1.10.3.1 Deals 339
16.1.11 BIO-RAD LABORATORIES, INC. 340
16.1.11.1 Business overview 340
16.1.11.2 Products offered 341
16.1.11.3 Recent developments 342
16.1.11.3.1 Product launches 342
16.1.12 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 343
16.1.12.1 Business overview 343
16.1.12.2 Products offered 343
16.1.12.3 Recent developments 344
16.1.12.3.1 Deals 344
16.1.13 FUJIREBIO 345
16.1.13.1 Business overview 345
16.1.13.2 Products offered 345
16.1.13.3 Recent developments 346
16.1.13.3.1 Deals 346
16.1.14 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 347
16.1.14.1 Business overview 347
16.1.14.2 Products offered 347
16.1.14.3 Recent developments 348
16.1.14.3.1 Product launches & approvals 348
16.1.14.3.2 Deals 348
16.1.15 AGAPPE DIAGNOSTICS LTD. 349
16.1.15.1 Business overview 349
16.1.15.2 Products offered 349
16.1.15.3 Recent developments 350
16.1.15.3.1 Deals 350
?
16.2 OTHER PLAYERS 351
16.2.1 ZECEN BIOTECH CO., LTD 351
16.2.2 MACCURA BIOTECHNOLOGY CO., LTD. 352
16.2.3 AUTOBIO DIAGNOSTICS 353
16.2.4 ARTRON LABORATORIES INC. 354
16.2.5 HUMAN GESELLSCHAFT F?R BIOCHEMICA UND DIAGNOSTICA MBH 355
16.2.6 ABNOVA CORPORATION 356
16.2.7 BEIJING HOTGEN BIOTECH CO., LTD. 357
16.2.8 ELABSCIENCE 358
16.2.9 GETEIN BIOTECH, INC. 359
16.2.10 SHANGHAI KEHUA BIO-ENGINEERING CO., LTD. 360
17 RESEARCH METHODOLOGY 361
17.1 RESEARCH DATA 361
17.1.1 SECONDARY DATA 362
17.1.1.1 Key data from secondary sources 363
17.1.1.2 Primary sources 363
17.1.1.3 Key data from primary sources 364
17.1.1.4 Breakdown of primaries 364
17.2 MARKET SIZE ESTIMATION 365
17.3 GROWTH FORECAST 369
17.4 MARKET BREAKDOWN & DATA TRIANGULATION 370
17.5 RESEARCH ASSUMPTIONS 372
17.6 RESEARCH LIMITATIONS 372
17.7 RISK ASSESSMENT 372
18 APPENDIX 373
18.1 DISCUSSION GUIDE 373
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 378
18.3 CUSTOMIZATION OPTIONS 380
18.3.1 GEOGRAPHIC ANALYSIS 380
18.3.2 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 380
18.3.3 COMPANY INFORMATION 380
18.3.4 PRODUCT TYPE ANALYSIS 380
18.3.4.1 By Analyzer (Semi and fully automated system) 380
18.3.4.2 By Technology (Breakdown by subcategories) 380
18.3.5 BY END USER ((BREAKDOWN BY SUBCATEGORIES) 380
18.3.6 BY MODE OF PURCHASE/BUSINESS MODEL 380
18.3.7 COUNTRY-LEVEL VOLUME ANALYSIS 380
18.3.8 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 380
18.3.9 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 380
?
18.4 RELATED REPORTS 381
18.5 AUTHOR DETAILS 382

ページTOPに戻る

List of Tables/Graphs

TABLE 1 INCLUSIONS AND EXCLUSIONS 37
TABLE 2 USD EXCHANGE RATES, 2020?2024 39
TABLE 3 INTERCONNECTED MARKETS 62
TABLE 4 CROSS-SECTOR OPPORTUNITIES 63
TABLE 5 KEY MOVES AND STRATEGIC FOCUS 63
TABLE 6 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
PORTER’S FIVE FORCES ANALYSIS 66
TABLE 7 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
SUPPLY CHAIN ANALYSIS (MICROBIOLOGY AGAR CULTURE PRODUCTS) 70
TABLE 8 ROLES OF COMPANIES IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES ECOSYSTEM 74
TABLE 9 IMPORT DATA RELATED TO HS CODE 902720-COMPLIANT PRODUCTS,
BY KEY COUNTRY, 2025?2022 (USD THOUSANDS) 79
TABLE 10 EXPORT DATA RELATED TO HS CODE 902720-COMPLIANT PRODUCTS,
BY KEY COUNTRY, 2025?2022 (USD THOUSANDS) 80
TABLE 11 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
LIST OF KEY CONFERENCES AND EVENTS, 2026?2027 81
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 84
TABLE 13 TOP USE CASES AND MARKET POTENTIAL 94
TABLE 14 BEST PRACTICES: COMPANIES IMPLEMENTING USE CASES 95
TABLE 15 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
CASE STUDIES RELATED TO GEN AI IMPLEMENTATION 95
TABLE 16 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 96
TABLE 17 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 112
TABLE 18 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 113
TABLE 19 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 113
TABLE 20 SOUTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 114
TABLE 21 GLOBAL INDUSTRY STANDARDS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET 114
TABLE 22 LABELING REQUIREMENTS AND CLAIMS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET 115
TABLE 23 CERTIFICATIONS, LABELLING, AND ECO-STANDARDS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET 117
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 120
TABLE 25 KEY CRITERIA FOR SELECTING SUPPLIERS/VENDORS 121
TABLE 26 UNMET NEEDS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT
& SUPPLIES MARKET, BY END-USE INDUSTRY 123
TABLE 27 COST DYNAMICS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT
& SUPPLIES MARKET 125
TABLE 28 MARGIN OPPORTUNITIES IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT
& SUPPLIES MARKET, BY TYPE 126
TABLE 29 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY TYPE, 2022?2025 (USD MILLION) 129
TABLE 30 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY TYPE, 2026?2031 (USD MILLION) 129
TABLE 31 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY SUBTYPE,
2022?2025 (USD MILLION) 131
TABLE 32 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY SUBTYPE,
2026?2031 (USD MILLION) 131
TABLE 33 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY SUBTYPE,
2022?2025 (NO. OF UNITS) 131
TABLE 34 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY SUBTYPE,
2026?2031 (NO. OF UNITS) 132
TABLE 35 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY REGION,
2022?2025 (USD MILLION) 132
TABLE 36 FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY REGION,
2026?2031 (USD MILLION) 132
TABLE 37 GENE TARGETS USED FOR FOOD PATHOGENS IN DEVELOPED PCR TESTS 134
TABLE 38 HYBRIDIZATION-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2022?2025 (USD MILLION) 135
TABLE 39 HYBRIDIZATION-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2026?2031 (USD MILLION) 135
TABLE 40 CHROMATOGRAPHY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY REGION, 2022?2025 (USD MILLION) 138
TABLE 41 CHROMATOGRAPHY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET, BY REGION, 2026?2031 (USD MILLION) 138
TABLE 42 SPECTROMETRY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2022?2025 (USD MILLION) 139
TABLE 43 SPECTROMETRY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2026?2031 (USD MILLION) 140
TABLE 44 IMMUNOASSAY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2022?2025 (USD MILLION) 141
TABLE 45 IMMUNOASSAY-BASED FOOD PATHOGEN SAFETY TESTING SYSTEMS MARKET,
BY REGION, 2026?2031 (USD MILLION) 141
TABLE 46 FOOD PATHOGEN SAFETY TESTING CONSUMABLES & SUPPLIES MARKET,
BY SUBTYPE, 2022?2025 (USD MILLION) 142
TABLE 47 FOOD PATHOGEN SAFETY TESTING CONSUMABLES & SUPPLIES MARKET,
BY SUBTYPE, 2026?2031 (USD MILLION) 143
TABLE 48 FOOD PATHOGEN SAFETY TESTING CONSUMABLES & SUPPLIES MARKET,
BY REGION, 2022?2025 (USD MILLION) 143
TABLE 49 FOOD PATHOGEN SAFETY TESTING CONSUMABLES & SUPPLIES MARKET,
BY REGION, 2026?2031 (USD MILLION) 143
TABLE 50 FOOD PATHOGEN SAFETY TEST KITS MARKET, BY REGION,
2022?2025 (USD MILLION) 145
TABLE 51 FOOD PATHOGEN SAFETY TEST KITS MARKET, BY REGION,
2026?2031 (USD MILLION) 145
TABLE 52 FOOD PATHOGEN SAFETY TEST KITS MARKET, BY REGION,
2022?2025 (MILLION TEST UNITS) 145
TABLE 53 FOOD PATHOGEN SAFETY TEST KITS MARKET, BY REGION,
2026?2031 (MILLION TEST UNITS) 146
TABLE 54 FOOD PATHOGEN SAFETY TESTING MICROBIAL CULTURE MEDIA MARKET,
BY REGION, 2022?2025 (USD MILLION) 147
TABLE 55 FOOD PATHOGEN SAFETY TESTING MICROBIAL CULTURE MEDIA MARKET,
BY REGION, 2026?2031 (USD MILLION) 147
TABLE 56 FOOD PATHOGEN SAFETY TESTING MICROBIAL CULTURE MEDIA MARKET,
BY REGION, 2022?2025 (TONS) 148
TABLE 57 FOOD PATHOGEN SAFETY TESTING MICROBIAL CULTURE MEDIA MARKET,
BY REGION, 2026?2031 (TONS) 148
TABLE 58 FOOD PATHOGEN SAFETY TESTING REAGENTS AND OTHER CONSUMABLES MARKET, BY REGION, 2022?2025 (USD MILLION) 150
TABLE 59 FOOD PATHOGEN SAFETY TESTING REAGENTS AND OTHER CONSUMABLES MARKET, BY REGION, 2026?2031 (USD MILLION) 150
TABLE 60 FOOD PATHOGEN SAFETY TESTING REAGENTS AND OTHER CONSUMABLES MARKET, BY REGION, 2022?2025 (MILLION TEST UNITS) 150
TABLE 61 FOOD PATHOGEN SAFETY TESTING REAGENTS AND OTHER CONSUMABLES MARKET, BY REGION, 2026?2031 (MILLION TEST UNITS) 151
TABLE 62 FOODBORNE PATHOGENS, BY FOOD SOURCE 153
TABLE 63 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 155
TABLE 64 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 156
TABLE 65 FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET
FOR MEAT & POULTRY, BY REGION, 2022?2025 (USD MILLION) 157
TABLE 66 FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET
FOR MEAT & POULTRY, BY REGION, 2026?2031 (USD MILLION) 157
TABLE 67 FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET
FOR FISH & SEAFOOD, BY REGION, 2022?2025 (USD MILLION) 158
TABLE 68 FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET
FOR FISH & SEAFOOD, BY REGION, 2026?2031 (USD MILLION) 158
TABLE 69 FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET
FOR DAIRY PRODUCTS, BY REGION, 2022?2025 (USD MILLION) 159
TABLE 70 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR DAIRY PRODUCTS, BY REGION, 2026?2031 (USD MILLION) 160
TABLE 71 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR PROCESSED FOOD, BY REGION, 2022?2025 (USD MILLION) 161
TABLE 72 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR PROCESSED FOOD, BY REGION, 2026?2031 (USD MILLION) 161
TABLE 73 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR FRUITS & VEGETABLES, BY REGION, 2022?2025 (USD MILLION) 162
TABLE 74 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR FRUITS & VEGETABLES, BY REGION, 2026?2031 (USD MILLION) 162
TABLE 75 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR CEREALS & GRAINS, BY REGION, 2022?2025 (USD MILLION) 163
TABLE 76 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR CEREALS & GRAINS, BY REGION, 2026?2031 (USD MILLION) 164
TABLE 77 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR OTHER FOOD PRODUCTS, BY REGION, 2022?2025 (USD MILLION) 165
TABLE 78 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
FOR OTHER FOOD PRODUCTS, BY REGION, 2026?2031 (USD MILLION) 165
TABLE 79 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2022?2025 (USD MILLION) 168
TABLE 80 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2026?2031 (USD MILLION) 168
TABLE 81 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN-HOUSE LABORATORIES, BY REGION, 2022?2025 (USD MILLION) 169
TABLE 82 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN-HOUSE LABORATORIES, BY REGION, 2026?2031 (USD MILLION) 169
TABLE 83 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN OUTSOURCING FACILITIES, BY REGION, 2022?2025 (USD MILLION) 170
TABLE 84 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN OUTSOURCING FACILITIES, BY REGION, 2026?2031 (USD MILLION) 170
TABLE 85 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN GOVERNMENT LABS, BY REGION, 2022?2025 (USD MILLION) 171
TABLE 86 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET IN GOVERNMENT LABS, BY REGION, 2026?2031 (USD MILLION) 172
TABLE 87 KEY EMERGING RAPID DETECTION PLATFORMS FOR FOOD PATHOGEN TESTING 176
TABLE 88 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY REGION, 2022?2025 (USD MILLION) 179
TABLE 89 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY REGION, 2026?2031 (USD MILLION) 180
TABLE 90 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY TYPE, 2022?2025 (USD MILLION) 181
TABLE 91 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY TYPE, 2026?2031 (USD MILLION) 181
TABLE 92 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SYSTEM, 2022?2025 (USD MILLION) 181
TABLE 93 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SYSTEM, 2026?2031 (USD MILLION) 181
TABLE 94 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET, BY SUBTYPE, 2022?2025 (USD MILLION) 182
TABLE 95 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET, BY SUBTYPE, 2026?2031 (USD MILLION) 182
TABLE 96 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 182
TABLE 97 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 183
TABLE 98 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SITE, 2022?2025 (USD MILLION) 183
TABLE 99 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SITE, 2026?2031 (USD MILLION) 183
TABLE 100 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY COUNTRY, 2022?2025 (USD MILLION) 184
TABLE 101 NORTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY COUNTRY, 2026?2031 (USD MILLION) 184
TABLE 102 US: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 185
TABLE 103 US: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 185
TABLE 104 CANADA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 186
TABLE 105 CANADA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 187
TABLE 106 MEXICO: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 188
TABLE 107 MEXICO: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 188
TABLE 108 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY TYPE, 2022?2025 (USD MILLION) 190
TABLE 109 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY TYPE, 2026?2031 (USD MILLION) 190
TABLE 110 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SYSTEM, 2022?2025 (USD MILLION) 191
TABLE 111 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SYSTEM, 2026?2031 (USD MILLION) 191
TABLE 112 EUROPE: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET,
BY SUBTYPE, 2022?2025 (USD MILLION) 191
TABLE 113 EUROPE: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET,
BY SUBTYPE, 2026?2031 (USD MILLION) 192
TABLE 114 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 192
TABLE 115 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 192
TABLE 116 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2022?2025 (USD MILLION) 193
TABLE 117 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2026?2031 (USD MILLION) 193
TABLE 118 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY COUNTRY, 2022?2025 (USD MILLION) 193
TABLE 119 EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY COUNTRY, 2026?2031 (USD MILLION) 194
TABLE 120 GERMANY: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 195
TABLE 121 GERMANY: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 195
TABLE 122 FRANCE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 196
TABLE 123 FRANCE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 197
TABLE 124 UK: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 198
TABLE 125 UK: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 198
TABLE 126 ITALY: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 199
TABLE 127 ITALY: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 199
TABLE 128 SPAIN: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 201
TABLE 129 SPAIN: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 201
TABLE 130 POLAND: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 202
TABLE 131 POLAND: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 202
TABLE 132 REST OF EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 203
TABLE 133 REST OF EUROPE: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 204
TABLE 134 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY TYPE, 2022?2025 (USD MILLION) 205
TABLE 135 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY TYPE, 2026?2031 (USD MILLION) 205
TABLE 136 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SYSTEM, 2022?2025 (USD MILLION) 206
TABLE 137 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SYSTEM, 2026?2031 (USD MILLION) 206
TABLE 138 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET, BY SUBTYPE, 2022?2025 (USD MILLION) 206
TABLE 139 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET, BY SUBTYPE, 2026?2031 (USD MILLION) 207
TABLE 140 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 207
TABLE 141 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 207
TABLE 142 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SITE, 2022?2025 (USD MILLION) 208
TABLE 143 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY SITE, 2026?2031 (USD MILLION) 208
TABLE 144 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY COUNTRY, 2022?2025 (USD MILLION) 208
TABLE 145 ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY COUNTRY, 2026?2031 (USD MILLION) 209
TABLE 146 CHINA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 210
TABLE 147 CHINA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 210
TABLE 148 JAPAN: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 211
TABLE 149 JAPAN: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 211
TABLE 150 INDIA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 212
TABLE 151 INDIA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 212
TABLE 152 AUSTRALIA & NEW ZEALAND: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 213
TABLE 153 AUSTRALIA & NEW ZEALAND: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 214
TABLE 154 SOUTHEAST ASIA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 215
TABLE 155 SOUTHEAST ASIA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 215
TABLE 156 REST OF ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 216
TABLE 157 REST OF ASIA PACIFIC: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 216
TABLE 158 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET, BY TYPE, 2022?2025 (USD MILLION) 217
TABLE 159 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY TYPE, 2026?2031 (USD MILLION) 217
TABLE 160 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY SYSTEM, 2022?2025 (USD MILLION) 218
TABLE 161 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY SYSTEM, 2026?2031 (USD MILLION) 218
TABLE 162 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING CONSUMABLES
& KITS MARKET, BY SUBTYPE, 2022?2025 (USD MILLION) 218
TABLE 163 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING CONSUMABLES
& KITS MARKET, BY SUBTYPE, 2026?2031 (USD MILLION) 219
TABLE 164 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 219
TABLE 165 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 219
TABLE 166 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY SITE, 2022?2025 (USD MILLION) 220
TABLE 167 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY SITE, 2026?2031 (USD MILLION) 220
TABLE 168 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY COUNTRY, 2022?2025 (USD MILLION) 220
TABLE 169 SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET, BY COUNTRY, 2026?2031 (USD MILLION) 220
TABLE 170 BRAZIL: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 221
TABLE 171 BRAZIL: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 221
TABLE 172 ARGENTINA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 222
TABLE 173 ARGENTINA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 223
TABLE 174 REST OF SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 224
TABLE 175 REST OF SOUTH AMERICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT
AND SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 224
TABLE 176 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET,
BY TYPE, 2022?2025 (USD MILLION) 225
TABLE 177 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET,
BY TYPE, 2026?2031 (USD MILLION) 225
TABLE 178 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET,
BY SYSTEM, 2022?2025 (USD MILLION) 225
TABLE 179 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET,
BY SYSTEM, 2026?2031 (USD MILLION) 226
TABLE 180 ROW: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET,
BY SUBTYPE, 2022?2025 (USD MILLION) 226
TABLE 181 ROW: FOOD PATHOGEN SAFETY TESTING CONSUMABLES & KITS MARKET,
BY SUBTYPE, 2026?2031 (USD MILLION) 226
TABLE 182 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 227
TABLE 183 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 227
TABLE 184 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2022?2025 (USD MILLION) 227
TABLE 185 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2026?2031 (USD MILLION) 228
TABLE 186 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY REGION, 2022?2025 (USD MILLION) 228
TABLE 187 ROW: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY REGION, 2026?2031 (USD MILLION) 228
TABLE 188 MIDDLE EAST: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2022?2025 (USD MILLION) 229
TABLE 189 MIDDLE EAST: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, BY FOOD TESTED, 2026?2031 (USD MILLION) 229
TABLE 190 AFRICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2022?2025 (USD MILLION) 230
TABLE 191 AFRICA: FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026?2031 (USD MILLION) 231
TABLE 192 OVERVIEW OF STRATEGIES ADOPTED BY KEY FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MANUFACTURERS 233
TABLE 193 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
DEGREE OF COMPETITION 238
TABLE 194 FOOD PATHOGEN SAFETY EQUIPMENT & SUPPLIES MARKET:
REGIONAL FOOTPRINT, 2025 245
TABLE 195 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
TYPE FOOTPRINT, 2025 246
TABLE 196 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
FOOD TESTED FOOTPRINT, 2025 247
TABLE 197 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
DETAILED LIST OF KEY STARTUPS/SMES, 2025 250
TABLE 198 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2025 251
TABLE 199 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
PRODUCT LAUNCHES, JANUARY 2022?FEBRUARY 2026 252
TABLE 200 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
DEALS, JANUARY 2022?FEBRUARY 2026 255
TABLE 201 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET: EXPANSIONS, JANUARY 2022?FEBRUARY 2026 259
TABLE 202 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
OTHER DEVELOPMENTS, JANUARY 2022?FEBRUARY 2026 261
TABLE 203 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 263
TABLE 204 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 264
TABLE 205 THERMO FISHER SCIENTIFIC INC.: DEALS 266
TABLE 206 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS 267
TABLE 207 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS 267
TABLE 208 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 269
TABLE 209 BIO-RAD LABORATORIES, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 271
TABLE 210 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES 272
TABLE 211 MERCK KGAA: BUSINESS OVERVIEW 274
TABLE 212 MERCK KGAA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 276
TABLE 213 MERCK KGAA: EXPANSIONS 277
TABLE 214 NEOGEN CORPORATION: BUSINESS OVERVIEW 279
TABLE 215 NEOGEN CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 281
TABLE 216 NEOGEN CORPORATION: PRODUCT LAUNCHES 282
TABLE 217 NEOGEN CORPORATION: DEALS 282
TABLE 218 SHIMADZU CORPORATION: BUSINESS OVERVIEW 284
TABLE 219 SHIMADZU CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 285
TABLE 220 SHIMADZU CORPORATION: PRODUCT LAUNCHES 286
TABLE 221 BIOM?RIEUX: BUSINESS OVERVIEW 287
TABLE 222 BIOM?RIEUX: PRODUCTS/SOLUTIONS/SERVICES OFFERED 289
TABLE 223 BIOM?RIEUX: PRODUCT LAUNCHES 290
TABLE 224 BIOM?RIEUX: DEALS 291
TABLE 225 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 292
TABLE 226 AGILENT TECHNOLOGIES, INC.: PRODUCT/SOLUTION/SERVICES OFFERED 293
TABLE 227 AGILENT TECHNOLOGIES, INC.: EXPANSIONS 294
TABLE 228 QIAGEN: BUSINESS OVERVIEW 295
TABLE 229 QIAGEN: PRODUCTS/SOLUTIONS/SERVICES OFFERED 297
TABLE 230 QIAGEN: PRODUCT LAUNCHES 298
TABLE 231 QIAGEN: DEALS 298
TABLE 232 BRUKER: BUSINESS OVERVIEW 299
TABLE 233 BRUKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED 301
TABLE 234 BRUKER: DEALS 301
TABLE 235 PERKINELMER INC.: BUSINESS OVERVIEW 303
TABLE 236 PERKINELMER INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 304
TABLE 237 PERKINELMER INC.: PRODUCT LAUNCHES 305
TABLE 238 PERKINELMER INC.: EXPANSIONS 305
TABLE 239 HYGIENA, LLC: BUSINESS OVERVIEW 306
TABLE 240 HYGIENA, LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 306
TABLE 241 HYGIENA, LLC: PRODUCT LAUNCHES 308
TABLE 242 HYGIENA, LLC: DEALS 308
TABLE 243 SOLABIA GROUP: BUSINESS OVERVIEW 310
TABLE 244 SOLABIA GROUP: PRODUCT/SOLUTION/SERVICES OFFERED 310
TABLE 245 SOLABIA GROUP: DEALS 312
TABLE 246 ROKA BIO SCIENCE: BUSINESS OVERVIEW 314
TABLE 247 ROKA BIO SCIENCE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 314
TABLE 248 PROMEGA CORPORATION: BUSINESS OVERVIEW 316
TABLE 249 PROMEGA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 316
TABLE 250 PROMEGA CORPORATION: DEALS 317
TABLE 251 ROMER LABS DIVISION HOLDING: BUSINESS OVERVIEW 318
TABLE 252 ROMER LABS DIVISION HOLDING: PRODUCTS/SOLUTIONS/SERVICES OFFERED 318
TABLE 253 CHARM SCIENCES: BUSINESS OVERVIEW 320
TABLE 254 CHARM SCIENCES: PRODUCT/SOLUTION/SERVICES OFFERED 320
TABLE 255 CHARM SCIENCES: OTHER DEVELOPMENTS 321
TABLE 256 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 322
TABLE 257 MICROBIOLOGICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 322
TABLE 258 MICROBIOLOGICS, INC.: DEALS 323
TABLE 259 R-BIOPHARM: BUSINESS OVERVIEW 324
TABLE 260 R-BIOPHARM: PRODUCT/SOLUTION/SERVICES OFFERED 325
TABLE 261 R-BIOPHARM: DEALS 326
TABLE 262 CONDALAB: BUSINESS OVERVIEW 327
TABLE 263 CONDALAB: PRODUCTS/SOLUTIONS/SERVICES OFFERED 327
TABLE 264 CHROMAGAR: BUSINESS OVERVIEW 329
TABLE 265 CHROMAGAR: PRODUCT/SOLUTION/SERVICES OFFERED 329
TABLE 266 GOLD STANDARD DIAGNOSTICS: BUSINESS OVERVIEW 331
TABLE 267 CLEAR LABS, INC.: BUSINESS OVERVIEW 332
TABLE 268 RING BIOTECHNOLOGY CO LTD.: BUSINESS OVERVIEW 333
TABLE 269 NEMIS TECHNOLOGIES AG: BUSINESS OVERVIEW 334
TABLE 270 PATHOGENDX CORPORATION: BUSINESS OVERVIEW 335
TABLE 271 KEY DATA FROM PRIMARY SOURCES 338
TABLE 272 RESEARCH ASSUMPTIONS 345
TABLE 273 RESEARCH LIMITATIONS AND RISK ASSESSMENT 346
TABLE 274 MARKETS ADJACENT TO FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND SUPPLIES MARKET 347
TABLE 275 FOOD SAFETY TESTING MARKET, BY TARGET TESTED, 2017?2021 (USD MILLION) 348
TABLE 276 FOOD SAFETY TESTING MARKET, BY TARGET TESTED, 2022?2027 (USD MILLION) 348
TABLE 277 FOOD DIAGNOSTICS MARKET, BY TYPE, 2018?2025 (USD MILLION) 349FIGURE 1 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET SEGMENTATION 36
FIGURE 2 STUDY YEARS CONSIDERED 38
FIGURE 3 MARKET SCENARIO 41
FIGURE 4 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, 2022?2031 42
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, JANUARY 2021?JANUARY 2026 42
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET 43
FIGURE 7 HIGH-GROWTH SEGMENTS IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT
& SUPPLIES MARKET 44
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 45
FIGURE 9 FOCUS ON ANIMAL HEALTH AND PRODUCTIVITY CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS 46
FIGURE 10 TYPE OF INSTRUMENT SEGMENT AND REGIONAL SHARE 47
FIGURE 11 OUTSOURCING FACILITIES SEGMENT TO LEAD IN MARLET IN 2026 47
FIGURE 12 MEAT & POULTRY SEGMENT TO LEAD MARKET IN 2026 48
FIGURE 13 TYPES OF SYSTEMS 49
FIGURE 14 TYPES OF CONSUMABLES & SUPPLIES 49
FIGURE 15 US TO DOMINATE MARKET IN 2026 50
FIGURE 16 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
FIGURE 17 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 18 WORLD POPULATION, BY ECONOMY, 1950?2050 (BILLION) 68
FIGURE 19 POPULATION GROWTH TREND, 1950?2050 (BILLION) 68
FIGURE 20 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
VALUE CHAIN (FOOD PATHOGEN TESTING KITS) 72
FIGURE 21 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
ECOSYSTEM ANALYSIS 73
FIGURE 22 AVERAGE SELLING PRICE OF FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES OFFERED BY KEY PLAYERS, BY SYSTEM, 2025 (USD/UNIT) 75
FIGURE 23 AVERAGE SELLING PRICE OF FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES, BY SYSTEMS, 2022?2025 (USD/UNIT) 76
FIGURE 24 AVERAGE SELLING PRICE OF TEST KITS, BY REGION, 2022?2025 (USD/TESTS) 76
FIGURE 25 AVERAGE SELLING PRICE OF MICROBIAL CULTURE MEDIA,
BY REGION, 2022?2025 (USD/KG) 77
FIGURE 26 AVERAGE SELLING PRICE OF REAGENTS & CONSUMABLES,
BY REGION, 2022?2025 (USD/TESTS) 77
FIGURE 27 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 82
FIGURE 28 INVESTMENT AND FUNDING SCENARIO, 2025 (USD MILLION) 82
FIGURE 29 PATENTS APPLIED AND GRANTED, JANUARY 2015?DECEMBER 2025 89
?
FIGURE 30 FUTURE APPLICATIONS 92
FIGURE 31 LEGISLATION PROCESS IN EU 103
FIGURE 32 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET
DECISION-MAKING FACTORS 119
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 120
FIGURE 34 KEY BUYING CRITERIA, BY TYPE 121
FIGURE 35 ADOPTION BARRIERS AND INTERNAL CHALLENGES 122
FIGURE 36 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY TYPE, 2026 VS. 2031 (USD MILLION) 129
FIGURE 37 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY FOOD TESTED, 2026 VS. 2031 (USD MILLION) 155
FIGURE 38 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET,
BY SITE, 2026 VS. 2031 (USD MILLION) 167
FIGURE 39 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET: GEOGRAPHIC SNAPSHOT 179
FIGURE 40 EUROPEAN FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET SNAPSHOT 190
FIGURE 41 ASIA PACIFIC FOOD PATHOGEN SAFETY TESTING EQUIPMENT AND
SUPPLIES MARKET SNAPSHOT 205
FIGURE 42 REVENUE ANALYSIS FOR KEY COMPANIES, 2022?2024 (USD BILLION) 236
FIGURE 43 SHARE OF LEADING COMPANIES IN FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET, 2025 238
FIGURE 44 COMPANY VALUATION OF KEY FOOD PATHOGEN SAFETY TESTING EQUIPMENT
& SUPPLY MANUFACTURERS, 2024 (USD BILLION) 240
FIGURE 45 EV/EBITDA OF KEY COMPANIES, 2024 240
FIGURE 46 BRAND COMPARISON ANALYSIS, BY TYPE 241
FIGURE 47 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 243
FIGURE 48 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
COMPANY FOOTPRINT, 2025 244
FIGURE 49 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 249
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 263
FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 270
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT 275
FIGURE 53 NEOGEN CORPORATION: COMPANY SNAPSHOT 280
FIGURE 54 SHIMADZU CORPORATION: COMPANY SNAPSHOT 285
FIGURE 55 BIOM?RIEUX: COMPANY SNAPSHOT 288
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 293
FIGURE 57 QIAGEN: COMPANY SNAPSHOT 296
FIGURE 58 BRUKER: COMPANY SNAPSHOT 300
FIGURE 59 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET:
RESEARCH DESIGN 336
FIGURE 60 KEY DATA FROM SECONDARY SOURCES 337
FIGURE 61 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION,
AND REGION 339
?
FIGURE 62 KEY INSIGHTS FROM INDUSTRY EXPERTS 339
FIGURE 63 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 341
FIGURE 64 SUPPLY-SIDE ANALYSIS: SOURCES OF INFORMATION AT EVERY STEP 342
FIGURE 65 FOOD PATHOGEN SAFETY TESTING EQUIPMENT & SUPPLIES MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 343
FIGURE 66 DATA TRIANGULATION 344